Arcutis Biotherapeutics Stock In The News
| ARQT Stock | USD 14.62 0.19 1.28% |
Our overall analysis of Arcutis Biotherapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Arcutis Biotherapeutics. The specific impact of Arcutis Biotherapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Arcutis Biotherapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Arcutis Biotherapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Arcutis Biotherapeutics Backtesting and Arcutis Biotherapeutics Hype Analysis. For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide.
Arcutis |
Arcutis Biotherapeutics Today Top News and Investor Outlook
Arcutis Biotherapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Arcutis and other traded companies coverage with news coverage. We help investors stay connected with Arcutis headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Arcutis Stock performance. Please note that trading solely based on the Arcutis Biotherapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Arcutis Biotherapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Arcutis earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Arcutis Biotherapeutics that are available to investors today. That information is available publicly through Arcutis media outlets and privately through word of mouth or via Arcutis internal channels. However, regardless of the origin, that massive amount of Arcutis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arcutis Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arcutis Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arcutis Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arcutis Biotherapeutics alpha.
Arcutis Largest EPS Surprises
Earnings surprises can significantly impact Arcutis Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | -0.42 | -0.33 | 0.09 | 21 | ||
2021-02-16 | 2020-12-31 | -0.88 | -0.79 | 0.09 | 10 | ||
2024-08-14 | 2024-06-30 | -0.52 | -0.42 | 0.1 | 19 | ||
2020-08-11 | 2020-06-30 | -0.84 | -0.94 | -0.1 | 11 | ||
2020-11-05 | 2020-09-30 | -0.9 | -1.01 | -0.11 | 12 | ||
2023-11-03 | 2023-09-30 | -0.86 | -0.73 | 0.13 | 15 |
Arcutis Biotherapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Arcutis Biotherapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
12th of March 2025
Disposition of 100 shares by Burnett Patrick of Arcutis Biotherapeutics at 10.03 subject t... at finance.yahoo.com
7th of March 2025
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic ... at gurufocus.com
5th of March 2025
Arcutis Biotherapeutics Inc Announces Grant of Restricted Stock Units to New Employees at gurufocus.com
3rd of March 2025
Disposition of 3263 shares by Matsuda Masaru of Arcutis Biotherapeutics at 13.0311 subject... at MacroaxisInsider
28th of February 2025
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting at gurufocus.com
26th of February 2025
Arcutis Biotherapeutics Inc Announces FDA Acceptance of sNDA for ZORYVE Cream for ... at gurufocus.com
24th of February 2025
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE... at finance.yahoo.com
5th of February 2025
Insider Sell Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc at gurufocus.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arcutis Biotherapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arcutis Biotherapeutics' short interest history, or implied volatility extrapolated from Arcutis Biotherapeutics options trading.
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.